Pipeline

April 15, 2019

Company	Drug/Device	Medical Condition	Status
Immatics	IMA203	solid tumors	Phase I trial initiated enrolling 15 subjects with relapsed and/or refractory solid tumors for which no standard of care therapy is available
Concert Pharmaceuticals, Inc.	CTP-692	schizophrenia	Phase I trial initiated
National Institutes of Health (NIH)	H1ssF_3928	flu	Phase I trial initiated
Synchron, Inc.	Stentrode in combination with BrainOS software	severe paralysis	Phase I trial initiated taking place at hospitals in Melbourne, Australia
Homology Medicines, Inc.	HMI-102	phenylketonuria (PKU)	Phase I/II trial initiated enrolling adults aged 18 to 55 years
NanOlogy	NanoDoce (sterile submicron particle docetaxel suspension)	bladder cancer	Phase I/II trial initiated
Provention Bio, Inc.	PRV-031 (teplizumab)	recent onset type 1 diabetes (T1D)	Phase III trial initiated enrolling 300 subjects aged 8-17 years with recent onset T1D at 80 centers worldwide
Pfizer	IBRANCE (palbociclib)	men with HR+, HER2- metastatic breast cancer	sNDA approval granted by the FDA
Synspira Therapeutics	SNSP113	cystic fibrosis (CF)	Orphan Drug designation granted by the EMA
Aggredyne, Inc.	AggreGuide A 100 ADP Assay testing cartridge	platelet testing technologies	Clearance granted by the FDA
Spry Health	Loop System	chronic obstructive pulmonary disease (COPD)	Clearance granted by the FDA
Viiv Healthcare	Dovato (combination of dolutegravir (DTG) and lamivudine (3TC))	HIV-1 in adults who had not received treatment before	Approval granted by the FDA
Amgen	Evenity (romosozumab-aqqg)	osteoporosis in postmenopausal women at high risk of breaking a bone (fracture)	Approval granted by the FDA